1-3 of 3
A. Douglas Laird
Close
Sort by
Journal Articles

Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL

Yaqi Zhao, A. Douglas Laird, Kathryn G. Roberts, Rolla Yafawi, Hagop Kantarjian, Daniel J. DeAngelo, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan O’Brien, Elias Jabbour, Ryan D. Cassaday, Melanie R. Loyd, Scott Olsen, Geoffrey Neale, Xueli Liu, Erik Vandendries, Anjali Advani, Charles G. Mullighan
Journal: Blood Advances
Blood Adv (2024) 8 (12): 3226–3236.
https://doi.org/10.1182/bloodadvances.2023012430
Published: 2024
Includes: Supplemental data
Journal Articles

G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL

Ilaria Iacobucci, Reiji Fukano, Jake D. Friske, Chunxu Qu, Laura J. Janke, Yaqi Zhao, Pradyuamna Baviskar, Emily A. Backhaus, Peter Chockley, Aman Seth, A. Douglas Laird, Anjali S. Advani, Charles G. Mullighan
Journal: Blood Advances
Blood Adv (2022) 6 (11): 3255–3259.
https://doi.org/10.1182/bloodadvances.2021004854
Published: 2022
Includes: Supplemental data
Journal Articles

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

Clinical Trials & Observations
Daniel J. DeAngelo, Wendy Stock, Anthony S. Stein, Andrei Shustov, Michaela Liedtke, Charles A. Schiffer, Erik Vandendries, Katherine Liau, Revathi Ananthakrishnan, Joseph Boni, A. Douglas Laird, Luke Fostvedt, Hagop M. Kantarjian, Anjali S. Advani
Journal: Blood Advances
Blood Adv (2017) 1 (15): 1167–1180.
https://doi.org/10.1182/bloodadvances.2016001925
Published: 2017
Includes: Supplemental data